Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
December 18, 2025
Congrats to Peel’s CEO for his talk at Colorectal Cancer Alliance‘s 2025 CureCRC Summit. PEEL-224 offers a new approach to treating cancer with better efficacy and less toxicity. Our company looks forward to continuing to test PEEL-224 in patients on multiple clinical trials.
PEEL-224 offers a new way of treating aggressive cancers like metastatic CRC. PEEL-224 is a new cancer medicine with a delivery optimized, novel TOPO1 inhibitor payload showing early promise for patients. Excited to introduce a new way to treat cancer with better efficacy and less toxicity.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
